Exploring the effects of vitamin K on knee osteoarthritis outcomes
The Role of Vitamin K on Knee Osteoarthritis Outcomes
This study is testing whether different doses of vitamin K can help older adults with knee osteoarthritis feel better and improve their knee health.
Quick facts
| Phase | Phase1; Phase2 |
|---|---|
| Study type | Interventional |
| Enrollment | 55 (estimated) |
| Ages | 60 Years and up |
| Sex | All |
| Sponsor | Boston University Academic / other |
| Locations | 1 site (Boston, Massachusetts) |
| Trial ID | NCT06385275 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the impact of different forms and doses of vitamin K supplementation on knee osteoarthritis outcomes in older adults. Participants aged 60 and above, diagnosed with knee OA, will be randomized to receive either vitamin K1 (500 µg or 1000 µg), vitamin K2 (MK-7, 300 µg), or a placebo. The study aims to determine the appropriate dosing and form of vitamin K that may improve biochemical measures related to knee OA. The trial is designed to provide insights into the potential benefits of vitamin K for this population.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals aged 60 and older with a clinical diagnosis of knee osteoarthritis.
Not a fit: Patients currently using anticoagulants such as warfarin or other blood thinners may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved management strategies for knee osteoarthritis in older adults through vitamin K supplementation.
How similar studies have performed: While some studies have explored vitamin K's effects in other conditions, this specific approach in knee osteoarthritis is novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * ≥60 years old * Clinical diagnosis of knee OA by the treating rheumatologist * English fluency Exclusion Criteria: * Anticoagulation use (including warfarin, dabigatran, rivaroxaban, apixaban)
Where this trial is running
Boston, Massachusetts
- Boston Medical Center, Rheumatology Clinic — Boston, Massachusetts, United States (Recruiting)
Study contacts
- Principal investigator: Jean Liew, MD MS — Boston University Chobanian & Avedisian School of Medicine, Department of Rheumatology
- Study coordinator: Jean Liew, MD MS
- Email: jwliew@bu.edu
- Phone: 617 358 9655
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.